Key Developments: Bio-Rad Laboratories Inc (BIOb.N)
115.50USD
21 May 2013
$-1.26 (-1.08%)
$116.30
$115.50
$115.50
$115.50
200
39
$125.50
$93.98
Latest Key Developments (Source: Significant Developments)
Bio-Rad Laboratories Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
Bio-Rad Laboratories Inc announced that for fiscal 2013, the Company is cautiously optimistic of achieving a currency-neutral sales growth guidance of 3% to 3.5% for the base business that the Company provided in February. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.15 billion for fiscal 2013. Full Article
Bio-Rad Laboratories Inc Issues FY 2013 Revenue Guidance Above Analysts' Estimates-Conference Call
Bio-Rad Laboratories Inc announced that for fiscal 2013, it expects currency neutral sales growth to be in the 3% to 3.5%. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.12 billion for fiscal 2013. Full Article
Bio-Rad Laboratories Inc Acquires AbD Serotec, Division Of MorphoSys AG
Bio-Rad Laboratories Inc announced that it has purchased AbD Serotec, a division of MorphoSys AG, for approximately 53 million euros in cash. AbD Serotec is one of the antibody manufacturers offering over 15,000 antibodies, kits, and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom, as well as other facilities in Germany and the U.S. Full Article
Bio-Rad Laboratories Inc Signs Definitive Agreement to Acquire AbD Serotec from MorphoSys AG
Bio-Rad Laboratories Inc announced that it has signed a definitive agreement to acquire AbD Serotec, a division of MorphoSys AG for EUR53 million in cash. The transaction is subject to certain closing conditions and is expected to be completed in January. Full Article
Circadian Technologies Ltd Enters Into License Agreement With Bio-Rad Laboratories, Inc.
Circadian Technologies Ltd announced that its wholly owned subsidiary, Vegenics Pty Ltd, has entered into a non-exclusive worldwide license agreement with one of the providers of life science research and clinical diagnostics products, Bio-Rad Laboratories, Inc., (NYSE: BIO and BIOb), to market research assays for the detection of VEGF-C and/or VEGF-D in biological fluids. Full Article
Bio-Rad Laboratories Inc Lowers FY 2012 Revenue Guidance-Conference Call
Bio-Rad Laboratories Inc announced that in the last call it has guided currency neutral revenue growth to be at the low end of 3.5% to 4.5% range for fiscal 2012. Given year to date currency neutral growth of about 2.7% and combined with the continued economic challenges, especially in the European region, it now believe the full year currency neutral sales growth for fiscal 2012 will likely remain in that same 2.5% to 3% range have experienced so far this year. The Company reported revenue of $2.074 billion in fiscal 2011. Full Article
Bio-Rad Laboratories Inc Acquires Cell Sorting System From Propel Labs
Bio-Rad Laboratories Inc announced that that they have acquired a new cell sorting system from Propel Labs. Under the terms of agreement, Bio-Rad has acquired an automated, easy-to-use benchtop sorting flow cytometer. The instrument will be offered by Bio-Rad as the S3(TM) Cell Sorter. First shipments are anticipated in January 2013. Other terms of the agreement were not disclosed. Full Article
Bio-Rad Laboratories Inc Sees FY 2012 Revenue Guidance At Bottom End Of Prior Range-Conference Call
Bio-Rad Laboratories, Inc. announced that its outlook for fiscal 2012 remains relatively unchanged from the guidance the Company provided in February 2012. The beginning of the year estimate for 3.5% to 4.5% currency neutral top line growth is still within sight, albeit more likely at the bottom end of that range, given the continued challenges in Europe, the Company's largest market. Full Article
Bio-Rad Laboratories, Inc. Reaffirms FY 2012 Revenue Guidance-Conference Call
Bio-Rad Laboratories, Inc. announced that fiscal 2012 outlook remains relatively unchanged from the guidance provided in February. The Company expects top line currency neutral organic growth to be in the 3.5% to 4.5% are range. The Company reported revenue of $2.073 billion in fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.138 billion for fiscal 2012. Full Article
David Schwartz, Bio-Rad Co-Founder and Chairman of Bio-Rad Laboratories, Inc.'s Board, Passes Away
Bio-Rad Laboratories, Inc. announced that David Schwartz, Bio-Rad Chairman of the Board and Co-founder, passed away on April 1, 2012. Full Article
DIARY-U.S. MEETINGS / DAY AHEAD
THOMSON REUTERS, Corporate Meetings for US Companies for Tuesday, February 12, 2013. S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly Non S&P 500 - Day Ahead ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day Meetings - Weekly S&P 500 Earnings - Monthly Economic Indicators Dividends Daily earnings hits & misses Federal Reser
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
